Azole antifungal prevention for leukemia during low white blood counts
Treatments studied
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can sign consent
- You have AML or MDS that has turned into AML, and you’re starting intensive chemotherapy
- You expect to be in the hospital during the period when neutrophils drop very low (absolute neutrophils <500)
- You do NOT already have a severe fungal infection from the last 3 months, and you don’t have mold infection at enrollment
- You cannot have certain allergies to azole antifungal medicines
- You can’t have major liver problems or a long QT heart rhythm measurement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This study tests an experimental drug called S241656, either alone or with another medication, for people with certain blood cancers (AML, MDS/AML, or CMML) that haven't responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
This trial tests whether giving a preventive antibiotic during chemotherapy can lower the risk of infections in people with certain blood cancers. It may help reduce hospital stays and improve treatment outcomes.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
Hear when a new Candidiasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.